Table 1 PD cohort characteristics.

From: Metabolic syndrome does not influence the phenotype of LRRK2 and GBA related Parkinson’s disease

 

iPD

LRRK2-PD

GBA-PD

significance

#

104

40

70

 

Age(y)

66.61 (10.43)

64.82 (10.03)

64.30 (9.78)

0.302

Disease duration (y)

2.55 (1.98)@

3.64 (2.52)

3.98 (2.65)

0.001

Sex m/f

71/33

24/16

46/24

0.644

LEDD

277.11 (279.11)@

432.67 (398.41)

468.16 (428.85)

0.002

Orthostatic Hypotension (%)

17.30%

10.00%

22.85%

0.233

MDS-UPDRS

38.14 (18.41)

35.35 (16.70)

43.77 (21.89)

0.077

MoCA

23.86 (3.75)

24.53 (4.44)

23.54 (3.85)

0.455

UPSIT

17.12 (9.87)

20.83 (9.47)#

14.51 (9.31)

0.008

RBDQ

3.06 (2.56)

3.08 (2.38)

3.95 (3.53)

0.291

NMSQ

7.46 (4.62)

6.74 (3.78)

8.55 (5.45)

0.083

SCOPA-AUT

16.93 (10.09)

18.03 (11.74)

17.11 (10.85)

0.478

BDI

8.00 (6.13)

6.93 (5.50)

9.31 (7.35)

0.169

  1. iPD – idiopathic Parkinson’s Disease, m-male, f-female, LEDD- LevoDopa Equivalent Daily Dose, MDS-UPDRS- Movement Disorder Society – Unified Parkinson’s Disease Rating Scale, MoCA – Montreal Cognitive Assessment, UPSIT- University of Pennsylvania Smell Identification Test, RBDQ- REM sleep Behavior Disorder Questionnaire, NMSQ- Non-Motor Symptoms questionnaire, SCOPA-AUT- Scale of Outcome in Parkinson’s Disease – Autonomic Dysfunction, BDI- Beck Depression Inventory.
  2. @Differences between iPD and LRRK2-PD and GBA-PD, #Differences between LRRK2-PD and GBA-PD
Back to article page